A Phase III, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Multicenter Evaluation of Civamide Nasal Solution 0.01% in the Prevention of Cluster Headaches During an Episodic Cluster Headache Period.

Trial Profile

A Phase III, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Multicenter Evaluation of Civamide Nasal Solution 0.01% in the Prevention of Cluster Headaches During an Episodic Cluster Headache Period.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Zucapsaicin (Primary)
  • Indications Cluster headache
  • Focus Therapeutic Use
  • Sponsors Winston Laboratories
  • Most Recent Events

    • 03 Oct 2017 Planned initiation date changed from 1 Nov 2017 to 1 Nov 2018.
    • 03 Oct 2017 Planned End Date changed from 1 Feb 2020 to 1 Feb 2021.
    • 03 Oct 2017 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top